**7. Conclusions**

*H. pylori* infection is detected significantly more often among patients with chronic liver injury. This is especially dangerous in patients with liver cirrhosis. In this group of patients, *H. pylori* infection may significantly worsen liver function, affecting hyperammonemia, increase in portal pressure, and development of esophageal varices. Testing for and treating this infection is of paramount importance for these patients.

[4] Wroblewski LE, Peek RM Jr. *Helicobacter pylori*, cancer, and the gastric microbiota. Advances in Experimental Medicine and Biology. 2016;**908**:393-408. DOI: 10.1007/

The Importance of *H. pylori* Infection in Liver Diseases http://dx.doi.org/10.5772/intechopen.79969

[5] Sun X, Xu Y, Wang L, Zhang F, Zhang J, Fu X, Jing T, Han J. Association between TNFA gene polymorphisms and *Helicobacter pylori* infection: A meta-analysis. PLoS One.

[6] Waluga M, Kukla M, Żorniak M, Bacik A, Kotulski R. From the stomach to other organs: *Helicobacter pylori* and the liver. World Journal of Hepatology. 2015;**7**(18):2136-2146. DOI:

[7] Suzuki H, Franceschi F, Nishizawa T, Gasbarrini A. Extragastric manifestations of *Helicobacter pylori* infection. Helicobacter. 2011;**16**(Suppl 1):65-69. DOI: 10.1111/j.1523-5378.

[8] Figura N, Palazzuoli A, Vaira D, Campagna M, Moretti E, Iacoponi F, Giordano N, Clemente S, Nuti R, Ponzetto A. Cross-sectional study: CagA-positive *Helicobacter pylori* infection, acute coronary artery disease and systemic levels of B-type natriuretic peptide. Journal of Clinical Pathology. 2014;**67**(3):251-257. DOI: 10.1136/jclinpath-2013-201743 [9] Wang JW, Tseng KL, Hsu CN, Liang CM, Tai WC, Ku MK, Hung TH, Yuan LT, Nguang SH, Yang SC, Wu CK, Chiu CH, Tsai KL, Chang MW, Huang CF, Hsu PI, Wu DC, Chuah SK. Association between *Helicobacter pylori* eradication and the risk of coronary heart

diseases. PLoS One. 2018;**13**(1):e0190219. DOI: 10.1371/journal.pone.0190219

[10] Yang YJ, Wu CT, Ou HY, Lin CH, Cheng HC, Chang WL, Chen WY, Yang HB, Lu CC, Sheu BS. Male non-insulin users with type 2 diabetes mellitus are predisposed to gastric corpus-predominant inflammation after *H. pylori* infection. Journal of Biomedical

[11] Rabelo-Gonçalves EM, Roesler BM, Zeitune JM. Extragastric manifestations of *Helicobacter pylori* infection: Possible role of bacterium in liver and pancreas diseases. World

[12] Guarneri C, Lotti J, Fioranelli M, Roccia MG, Lotti T, Guarneri F. Possible role of *Helicobacter pylori* in diseases of dermatological interest. Journal of Biological Regulators

[13] Pellicano R, Menard A, Rizzetto M, Megraud F. *Helicobacter* species and liver diseases: Association or causation? The Lancet Infectious Diseases. 2008;**8**:254-260. DOI: 10.1016/

[14] Goo MJ, Ki MR, Lee HR, Yang HJ, Yuan DW, Hong IH, Park JK, Hong KS, Han JY, Hwang OK, Kim DH, Do SH, Cohn RD, Jeong KS. *Helicobacter pylori* promotes hepatic fibrosis in the animal model. Laboratory Investigation. 2009;**89**:1291-1303. DOI: 10.1038/

[15] Stalke P, Al-Soud WA, Bielawski KP, Bakowska A, Trocha H, Stepinski J, Wadstrom T. Detection of *Helicobacter* species in liver and stomach tissues of patients with chronic liver diseases using polymerase chain reaction-denaturing gradient gel electrophoresis

Journal of Hepatology. 2015;**7**(30):2968-2979. DOI: 10.4254/wjh.v7.i30.2968

2016;**11**(1):e0147410. DOI: 10.1371/journal.pone.0147410

Science. 2017;**24**(1):82. DOI: 10.1186/s12929-017-0389-x

and Homeostatic Agents. 2017;**31**(Suppl. 2):57-77

S1473-3099(08)70066-5

labinvest.2009.90

978-3-319-41388-4\_19

10.4254/wjh.v7.i18.2136

2011.00883.x

Current research on the impact of *H. pylori* infection in patients with chronic liver damage is inadequate. This points to the desirability of further research, particularly among patients with severe liver damage.
